Strausberg, 8 November 2023
Today, DERMAGO GmbH, headquartered in Strausberg, has announced that Mittelständische Beteiligungsgesellschaft Berlin-Brandenburg GmbH (MBG) is to invest EUR 300,000 in the company group in the form of a silent partnership.
The new capital will be used for the financing of new clinical development projects as well as for further investments in the in-house laboratory.
Sven Schimansky-Wabra, CEO of DERMAGO, states: “I am delighted that MBG has joined DERMAGO as a silent partner! This partnership is an exciting step towards innovation and sustainable growth in our region.
The fact that MBG has joined our company is not only a sign of confidence in our vision, but also a strong commitment to promoting entrepreneurship and economic development in our home region. This cooperation enables us to realize our ambitious plans for the further development of DERMAGO.
From the very beginning, our mission has been to revolutionize the healthcare industry through innovative solutions and with this new partnership, we will further strengthen our efforts.”
Stefanie Richter, DERMAGO’s CFO, adds: “We are proud to have the support of MBG at our side and we are determined to jointly leave a positive impact on healthcare and the economy of our region.”
DERMAGO GmbH is a service company specializing in the development of unique generic versions and original preparations of prescription-only, reimbursable dermatological pharmaceutical products and bringing them through the pharmaceutical marketing authorization process under its own management.
In addition, the services of DERMAGO GmbH include consulting activities, scientific assessments, the preparation of expert opinions as well as qualitative and quantitative studies, especially for dermatological pharmaceutical products. The development of analytical methods and procedures as well as services for the marketing authorization of pharmaceutical products are also part of DERMAGO’s range of services.